Table 2.
Relationship between ZFP36L2 expression and clinicopathological characteristics of cervical cancer patients.
| Characteristics | Cases (n = 57) | ZFP36L2 expression |
P-values |
|
|---|---|---|---|---|
| Positive (n = 35) | Negative (n = 22) | (chi-square test) | ||
| Age (year) | 0.366 | |||
| <50 | 32 | 18 | 14 | |
| ≥50 | 25 | 17 | 8 | |
| Tumor size (cm) | 0.019* | |||
| <4 | 42 | 22 | 20 | |
| ≥4 | 15 | 13 | 2 | |
| FIGO stage | 0.124 | |||
| I-II | 38 | 26 | 12 | |
| III | 19 | 9 | 10 | |
| Differentiation | 0.724 | |||
| Well, moderate | 48 | 29 | 19 | |
| Poor | 9 | 6 | 3 | |
| HPV status | 0.405 | |||
| Negative | 35 | 20 | 15 | |
| Positive | 22 | 15 | 7 | |
| Lymph node metastasis | 0.004* | |||
| Negative | 39 | 19 | 20 | |
| Positive | 18 | 16 | 2 | |
Note: *p < 0.05; FIGO, international federation of gynecology and obstetrics.